ročník 2,1994 č.4


  1. Palliative treatment of liver tumours
  2. Portal Hypertension - State of the Art (Part 2)


  1. Zobrazování jaterních metastáz pomocí značených monoklonálních protilátek


Palliative treatment of liver tumours

Jeppsson,B., Persson,B.
Department of Surgery, Lund University Hospital

In a recent article by professor Bengmark on the palliative management of hepatic tumours the objective of such a treatment was highlighted (1). It was stated that palliative treatment should be developed which is simple, can be performed on a ambulatory basis for life, involves active participation by the patient and which has monimal or no side effects. Such treatment should not reduce mental or physical activity. No such treatment exist today.
What should be the goals for palliative treatment? The ultimate goal is to prolong symptoms-free survival, but also to relieve symptoms, an effect which is not defined or observed in many of the studies performed.
The resectability rate of primary liver cancer and metastasis is low and mostly below 20% (2). The natural history of patients with untreated primary liver cancer and metastases is also low. For primary liver cancer a median survival of 6 months is often reported and for metastases at the most 18 months. Therefor, the majority of patients with liver tumors will be referred for palliative treatment. When talking about liver metastases in this context it almost refers to colorectal liver metastases.
Many palliative treatments have been suggested and I will give my opinion on a few shown in table 1. The multitude of therapies indicates that no one is clearly effective.
Tabl.1 - Palliative treatment
Chemotherapy systemic, local
biologic therapy
hormonal therapy
Interstitial therapy hypothermia
alcohol injection
ionizing radiation
Ischaemic therapy embolisation


Systemic chemotherapy in primary liver cancer has usually included doxorubicin or epirubicin. Response rates of 10 to 50% are generally reported but no prolongation of survival has been achieved. The toxic side effects are also considerable (3).
Several regimens of systemic chemotherapy have been used in the treatment of colorectal liver metastases and they iclude 5-FUDR, BCNU, Mitomycin, Methotrexat and Cisplatin. Response rates are generally lower than for primary liver cancer and no prolongation of survival has been achieved so far (4). Prospective randomized control trials in this group of patients are lacking. Nonetheless it appers that systemic chemotherapy results in relative low response rates for colorectal liver metastases with some but minimal effect on survival. In a recent study it was shown that the systemic chemotherapy could be performed with an improvement or stabilization of quality of life in more than half of patients with advanced colorectal cancer (5).
The administration of cytotoxic drugs and degradable starch microspheres (DSM) in the hepatic artery causes a selective increase in tumor concentration not by reduction in the elution but instead of increasing tumour perfusion. A number of phase 2 studies have now been undertaken in patients with hepatic metastases using DSM with a variety of cytotoxic agents. Objective response in terms of partial or complete tumor regression is reported in between 20 and 50% of patients (6). The number of patients is small however. Side effects include nausea, vomiting and epigastric pain. Hepatic artery tromboses and gastritis have also been reported. This route of therapy must be further exploited and the role of sequential administration should be evaluated. The use is not restricted to the delivery of conventional cytotoxic drug but also monoclonal antibodies and to produce regional hypothermia.

primary liver cancer has not been widely applied. The regional aplication of doxyrubicin has no advantage compared to systemic administration (7). Other combination have been used with FUDR and Mitomycin C. Some prolongation of life has been proposed bu no control study has been performed. Some has shown though that this treatment can be performed with good quality of life for the patients. It must be confirmed however in carefully controlled studies. Local intraarterial chemotherapy of colorectal liver metastases with 5-FUDR has been tried extensively. Response rates of 50 to 90% have been observed and the survival benefits compared to historic controls and compared to intravenous infusion have been achieved (8,9). There is however high complication rate especially with the use of implantable pumps with biliary sclerosis etc. Randomized studies with untreated controls areremarkably rare. It is hard to explain the lack of demostrable survival advantages with such high response rates because the presence of liver metastases has a significant negative impact on survival compared with metastases in other non-vital organs which rarely cause the death of patients. Several factors may explain this:
1 - De novo resistance.
Approximately 50% of patients never respond to arterial infusion despite adequate concentration of FUDR in the liver. The reasons for the de novo resistance are not clear.
2 - Acquired resistance.
Acquired resistance may be manifested by an initial response to therapy and the subsequent emergence of resistance. These two problems may by prevented or modulated with the addition of interferon alfa.
3 - Extra hepatic tumour progression.
Despite adequate response in the liver systemic failure has been reported in up to 50% pf patients, most commonly in the lungs. Some combination with systemic therapy may be advisable.
4 - Toxicity.
Hepatico-biliary and other toxicity may limit treatment benefit.
Chemotherapy has also been applied in a regional isolated perfusion system. Only small series of patients with liver tumors of different origins have been presented (10,11). The complication rate is rather high and today the isolation procedure is a major surgical intervention and I do not think it is applicable to this group of patients until the isolation can be performed percutaneously. Besides this many drugs have a dose limiting hepatotoxicity in the isolated system and this therefore futher hampers the effect. By using drugs whick lack hepatic toxicity but have severe systemic side effects, the isolated perfusion system may offer some advantage. We have performed a series of experiments where have tried to metabolically manipulate the liver tumors by interfering with glycolysis and protein synthesis (12).

Interstitial therapy

Interstitial therapy may be defined as a method of treatment where the therapeutic stimulus is delivered to the liver directly to the selected site of intended tissue damage. The intent is to reduce the volume of viable tumor or preventing futher tumor growth and improve length of survival. The attractions of the use of hypothermia are the increased heat sensitivity of neoplastic cells. There seems to be little consistent difference between the response if normal and neoplastic cells with the exclusion possibly at low pH. Therefore hyperthermia must be applied locally. Radiofrequency and microwave technique and application of ultrasound have been used but they are impractical because they are invasive when used in the liver. Lasertherapy is more attractive since it can be used by a percutaneous approach. Single fibre treatment can produce areas of necrosis up to 1,5 cm and with fibres activated simultaneously this can be increased to 4 cm. Several studies have been using this technique. The first two studies have used it at surgery in patients with primary and secondary tumours (13,14).
In both studies a decrease in AFP and CEA levels was achieved but follow up was short. In the study by Schröder there were complications with infections and air embolus (14). In the study from U.K. a percutaneous approach was used and a tumour response was see in 60% of the patients. 40% did not respond at all. In two out of 13 patients disseminated disease was apparent (15). It is difficult to judge effect on survival and it can be concluded that laserhyperthermia is still at the stage of pilot clinical studies.
Cryotherapy is the application of a cooling agent, usually liquid nitrogen. This leads to irreversible cell damage but also more remote effect within the body with immunological response to recidual viable tumour. This is thought to be the result of liberation of antigen but it is not clear if this has any clinical relevance (10). Several studies using this technique in the laboratory animal have published. In a first clinical study by Zhou et al.(17) of primary liver cancer a one year survival rate of 52% was achieved, in other studies with metastatic lesions a decrease in CEA levels could be observed (18). The main disadvantage of the technique is that patients have to undergo laparotomy. Modern technology may the application devises.
Percutaneous alcohol injection has gained wide spread use and is of potential interest. It can be applied to tumours of less than 3 cm in diameter and usually volumes of 5 to 10 ml up to 99 ml per lesion have been used. If larger lesions are injected a high incidence of remaining malignant cells and no evidence of regression is observed. It has been used with very few complications and impressive results in patients with irresectable primary liver cancer have been achieved with one year survival rates of 92% and 5 years survival rate of 60% (19-22). There are some reports of implantation metastases along the injection needle tract but this can probably be avoided by an improved technique. Alcohol is toxic and pain and some damage to surrounding liver tissue us observed.
The case for alcohol injection is becoming stronger. Its advantages are many including minimal demand on manpower and equipment. A futher improvement in results may be by combination with embolization.
Radiotherapy. Conventional external radiotherapy has little to recommend for palliation of hepatic tumours. There is a limit to the dose that can be applied. In an attempt to overcome this problem the technique of intraoperative radiotherapy (IORT) has been used (23). The rationale is that a much higher dose can be delivered to the tumour with little effect on the normal surrounding parenchyma or other organs (24). No controlled studies are available on liver tumours and we do not know any effect on survival or symptom relief. Another way of local radiotherapy is by interstitial radiotherapy. This is used by local application of 192 Iridium seeds (25) and Ytrium-90 microspheres (26,27). Any number of lesions can be treated at laparotomy with the seeds. The microspheres are injected at angiography. There are few uncontrolled studies but all that can be said from these is that the techniques are feasible but the follow up is too short to comment on survival.

Biological treatments

Biological treatment of cancer has evolved during the last decade and is based on a stimulation of the natural immune reactions against the disease. It can be defined as a cancer treatment that acts primarily through natural host defense mechanisms or the administration of natural mammalian substances (28). This therapy includes administration of interleukin 2 (IL-2), lymphokine activated killer cells (LAK) or tumour necrosis factor (TNF) either systemically or locally. Although the treatment is attractive results so far have been disapoiting with no response in colorectal liver cancer with administration of IL-2 alone and a response rate of 13% when combining IL-2 and LAK cells (29). The side effects with the systemic administrations are also significant.
The administration of TNF experimentaly is associated with a greater antitumour activity (30). However also here the dose limiting toxicity is severe (31). The regional application of TNF intraarterially seems attractive and it has been used in some case reports in the treatment of hepatocellular carcinoma combined with embolization and local hyperthermia (32). The results in colorectal liver metastases are not good (33,34). The rate of objective is however not impressive and the duration is very short.
It is well known that primary liver cancer express several hormone receptors such as estrogen receptors, androgen receptors among others. It is therefore attractive to treat irresectable primary liver cancers with tamoxifen. In one randomized study some encouraging results was reported with one year survival rate of 40% in a group of patients treated with tamoxifen 30 mg/day compared to 0 in an untreated control group (35). If these results are confirmed they represent an excellent advantage. However another study from King°s College has not been able to confirm this where in a controlled trial involving 59 patients comparing tamoxifen + doxorubicin with doxorubucin alone. There was no difference in the response rate and the survival rate of the two groups, unfortunately (36). A more recent study confirm the effectiveness of tamoxifen as a palliative measure and I think it should be tried in patients not possible to treat otherwise (37).

Ischaemic therapy

Hepatic artery embolization in combination with chemotherapy was developed in Japan for unresectable cases of hepatocellular carcinoma. Embolization is performed either with gelatin sponges in combination with cytotoxic drugs doxorubicin or mitomycin with the combination of Lipiodol or by Lipiodol and doxorubucun. Several studies have shown that this treatment achieves high concentrations of chemotherapeutic agent in the tumour and induce tumour necrosis (38,39). Several studies have shown very beneficial effects of this treatment. One year survival rates ranging from 40% to 100% have been achieved and 5 years survival rates of 5% to 20% in irresectable primary liver cancer. It has also been used in the treatment of local recurrencies in the liver after resection with remarkable results (40). Several studies have proven its efficacy versus systemic chemotherapy and embolization without Lipiodol (41). The tumour size is of no importance for the effectiveness of embolization but uninodular tumours have better results (42). The morbidity rate is between 10% and 15% and the major complications include liver failure with encephalopathy and ascites, cholecystitis and renal insufficiensy. It is important to note that many reports include symptomatic improvement in abdominal pain and general improvement in patients who were debilitated prior to treatment (43).
The use of embolization in patients with liver metastases has not been so effective. Usually a similar approach has been applied as for primary liver cancer but the effect on survival is very limited. The principal indication for its use is the amelioration of symptoms directly attributable to liver metastases such as local pain or the unpleasant humoral effects produced by secondary deposits from active endocrine tumours. The amelioration of symptoms can be achieved in 75% of the patients (44,45). This is especially true in patients with metastases from endocrine tumours. Complications are frequent and include pain, pyrexia, leucocytosis in half of the patients but more serious complication such as infection, gastrointestinal complications and renal failure are rare between 2% and 5%. Mortality rates of 1% to 22% have been reported.
The difference between blood supply of normal and tumour tissue can be utilized also in other ways. A true ischaemic insult can be inflicted by hepatic arterial ligation. Preformed arterial collaterals make the ischaemic effect only transient and therefore a more complete dearterialization of the liver has been proposed. This is a large operative procedure and performed alone or in combination with cytotoxic drug therapy, no survival benefit has been proven either in primary liver cancer or in metastatic liver disease. A rather high complication rate has also been reported (46). Since a few years we have tried to modify this concept by performing the dearterialization procedure repeatedly and transiently. For this purpose we have constructed a small vascular balloon occluder which is placed around the hepatic artery at laparotomy. Complete mobilization of the liver is also performed. Therafter pulsed ischaemic periods can be instituted by the patient himself by inflating the balloon. This can then be combined with cycling of cytotoxic drug administration. In animal experiments we have shown that short episods of ischaemia up to 2 hours do not induce the formation a-v collaterals. Upon occlusion there seems to be a generation of oxygen free radicals that might be cytotoxic in the tumour tissue upon reestablishment of the arterial circulation and increased DNA synthesis occurs which can be utilized when combined with cytotoxic drug therapy. With this therapy we have treated 25 patients in a first trial (47). Four patients with primary liver cancer all had signs of tumour regression, in one patients so much that he could be resected 6 months after institution of therapy. In patients with colorectal liver metastasis diseases the response is more varied with an overall median survival of 18 months and an objective tumour response in about 50% of the patients. Symptomatic relief is achieved in the majprity of patients with reduction of hepatomegaly. The psychological benefit which the patient gets from performing the treatment himself may also be of value. A randomized trial comparing this treatment to regional cytotoxic alone is in progress.
In summary, it can be stated that in the palliative treatment of liver tumours control studies are lacking, therefore fopefully in the future more patients will be inckuded in controlled studies. There is some support to recommend that in patients with irresectable primary liver cancer a palliative effect can be reached by administration of tamoxifen, alcohol injection or chemoembolization. For metastatic liver disease recommendations are harder to given. There is some evidence that regional chemotherapy may be beneficial. Alcohol injection technique can be applied and percutaneous laser application should be evaluated.


  1. Bengmark,S.: Palliative treatment of hepatic tumours. BJS 76,1989,771-773.
  2. Foster,J.H.: Surgical treatment of metastatic liver tumors. Hepato-gastroenterol.37,1990,182-187.
  3. Nerestone,S.R.,Ihde,D.C.,Friedman,M.A.: Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat.Rev.,15,1988,1-31.
  4. Hunt,T.M.,Taylor,I.: The role of chemotherapy in the treatment and prophylaxis colorectal liver metastases. Cancer Surveys 8,1989,71-9O.
  5. Glimelius,B., Hoffman,K.,Graf,W. et al.: Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 73,1994,556-562.
  6. Ball,A.B.S.: Regional chemotherapy for colorectal hepatic metastases using degradable microspheres. Acta Oncologica 30,1991,309-313.
  7. Kalayci,C.,Johnsson,P.J.,Raby,N. et al.: Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. J.Hepatol.,11,1990,349-353.
  8. Patt,Y.Z.,Mavligit,G.M.: Arterial chemotherapy in the management of colorectal cancer: An overview. Sem.Oncol.,18,1991,478-490.
  9. Kemeny,N.: Review of regional therapy of liver metastases in colorectal cancer. Sem.Oncol.,19,1992,155-162.
  10. Aigner,K.R.: Isolated liver perfusion: 5 year results. Reg.Cancer Treat.,1,1988,11-20.
  11. Beheshti,M.V.,Denny Jr.,D.F.,Glickman,M.G. et al.: Percutaneous isolated liver perfusion for treatment of hepatic malignancy: preliminary report. JVIR 3,1992,453-458.
  12. Cay,O.,Radnell,M.,Jeppsson,B. et al.: Inhibitory effect of 2-dexy-D-Glucose on liver tumor growth in rats. Cancer Research 52,1992,1-4.
  13. Hashimoto,D.,Takami,M.,Ideezuki,Y.: In depth radiation therapy by Nd:YAG laser for malignant tumours of the liver under ultrasonic imaging. Gastroenterology 88,1985,1663.
  14. Schröder,T.,Hahl,J.: Laser induced hyperthermia in the treatment of liver tumours. Lasers Surg.Med.(Suppl)1,1989,53.
  15. Masters,A.,Steger,A.C.,Brown,S.G.: Role of interstitial therapy in the treatment of liver cancer. BJS 78,1991,518-523.
  16. Jacob,G.,Li,A.K.C.,Hobbs,K.E.F.: A comparison of cryodestruction with excision or infarction of an implanted tumour in rat liver. Cryobiology 21,1984,148-156.
  17. Zhou,X.D.,Tang,Z.Y.,Yu,Y.Q. et al.: Clinical evaluation of cryosurgery in the treatment of primary liver cancer. Cancer 61,1988,1889-1892.
  18. Charnley,R.M.,Doran,J.,Morris,D.L.: Cytotherapy for liver metastases: a new approach. BJS 76,1989,1040-1041.
  19. Livraghi,T.,Festi,D.,Monti,F. et al.: US-guided percutaneous alcohol injection of small hepatic and abdominal tumours. Radiology 61,1986,309-312.
  20. Livraghi,T.,Salmi,A.,Bolondi,L. et al.:Small hepatocellular carcinoma: percutaneous alcohol - results in 23 patients. Radiology 168,1988,313-317.
  21. Shina,S.,Yasuda,H.,Muto,H. et al.: Percutaneous ethanol injection in the treatent of liver neoplasms. AJR 149,1987,949-952.
  22. Giovanni,M.,Seitz,J.F.: Ultrasound - guided percutaneous alcohol injection of small liver metastases. Cancer 73,1994,294-297.
  23. Nauta,R.J.,Heres,E.K.,Thomas,D.S. et al.: Intraoperative single dose radiotherapy. Arch.Surg.,122,1987,1392-1395.
  24. Gunderson,L.L.: Rationale for and results of intraoperative radiation therapy. Cancer 74,1994,537-541.
  25. Dritschilo,A.,Grant,E.G.,Harter,K.W. et al.: Interstitial radiation therapy for hepatic metastases: sonographic guidance for applicator placement. AJR 146,1986,275-278.
  26. Shephard,F.A.,Rotstein,L.E.,Houle,S. et al.: A phase I dose escalahon trial of Istrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 70,1992, 2250-2254.
  27. Lau,W.Y.,Leung,T.W.T.,Ho,S. et al.: Internal radiation therapy with Istrium-90 microspheres for inoperable hepatocellular carcinoma. Presented at World Congress of IHPBA, Boston, USA, May 31 - June 3,1994.
  28. Rosenberg,S.A.: Immunotherapy and gene therapy of cancer. Cancer Research (Suppl.)51,1991,5174-5079s.
  29. Rosenberg,S.A.,Lotze,M.T.,Yang,J.C. et al.: Experience with the use of high-dose interleukin-2 in the treatment of 652 patients with cancer. Ann.Surg.,210,1989,474-485.
  30. Bentler,B.,Cerami,A.: Cachectin: more than a tumor necrosis factor. NEJM 316,1987,379-385.
  31. Kemeny,N.,Childs,B.,Larchian,W. et al.: A phase I trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 66,1990,659-663.
  32. Maeda,M.,Watanabe,N.,Yamauchi,N. et al.: Successful treatment of a case of hepatocellular carcinoma with tumor necrosis factor and local hyperthermia. Gastroenterologica Japonica 26,1991,774-778.
  33. Mavligit,G.M.,Zukiwsky,A.A.,Charnsangavei,G. et al.: Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases. Cancer 69,1992,557-561.
  34. Van der Schelling,GP.,Jizermans,J.N.M., Kok,T.C. et al.: A phase I study of local treatment of liver metastases with recombinant tumour necrosis factor. Eur.J.Cancer 28,1992,1077-1078.
  35. Farinati,F.,Salvagnini,M.,DiMaria,F. et al.: Unresectable hepatocellular carcinoma: a prospective controledtrial with tamoxifen. J.Hepatol.,11,1990,297-301.
  36. Melia,W.M.,Johnson,P.J.,Williams,R.: Controlled clnical trial of doxorubicin and tamoxifen vs.doxorubicin alone in hepatocellular carcinoma. Cancer Treat.Rev.,71,1987,1213-1216.
  37. Boix,L.,Bruix,J.,Castells,A. et al.: Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment? J.Hepatol.,17,1993,187-191.
  38. Kasugai,H.,Kojima,J.,Tatsuta,M. et al.: Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of Cisplatina and Ethiodized oil. Gastroenterology 97,1989,965-971.
  39. Vetter,D.,Wenger,J.J.,Bergier,J.M. et al.: Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a western comparative study in 60 patients. Hepatology 13,1991,427-433.
  40. Furuta,T.,Kanematsu,T.,Matsumata,T. et al.: Lipoidolization prolongs survival rates in postoperative patients with a recurrent hepatocellular carcinoma. Hepato-gastroenterol.,37, 1990,494-497.
  41. Kalayci,C.,Johnson,P.J.,Raby,N. et al.: Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. J.Hepatol.,11,1990,349-353.
  42. Taniguchi,K.,Nakata,K.,Kato,Y. et al.: Treatment of hepatocellular carcinoma with transcatheter arterial embolization. Cancer 73,1994,1341-1345.
  43. Bismuth,H.,Morino,M.,Scherlock,D. et al.: Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am.J.Surg.,163,1992,387-394.
  44. Allison,D.J.,Booth,A.: Arterial embolization in the management of liver metastases. Cardiovasc.Intervent.Radiol., 13,1990,161-168.
  45. Guthric,C.M.,Leahy,A.L.,Redhead,D.N. et al.: Transcatheter hepatic therapy for symptomatic liver malignancy. J.R.Coll.Surg.Edinb.,36,1991,384-387.
  46. Bengmark,S.,Persson,B.,Jeppsson,B.: Ischaemia therapy of liver tumours. In: Surgery of the liver and biliary tract. Ed. by Blumgart,L.S.,Churchill Livingstone,New York,1994,1433-1462.
  47. Persson,B.G.,Jeppsson,B.,Ekberg,H. et al.: Repeated dearterialisation of hepatic tumours with an implantable occluder. Cancer 66,1990,1139-1146.
Adresa pro korespondenci:
Bengt Jeppsson,MD.,PhD.
Department of Surgery
Lund University Hospital
221 85 LUND - Sweden
(První díl v čísle 94-3.)

Portal Hypertension - State of the Art

(2nd part)
Paquet, K.J.
Hans-Kalk Hospital, Bad Kissingen

Role of liver transplantation

Liver transplantation (LT) is hypothetically the most logical treatment for bleeding esophageal varices in patients with advanced liver disease in recent reports (82,83). Starzl°s group has described their experience in 1000 patients undergoing LT. Of these 302 had a history of variceal hemorrhage before LT and all were Child class C. The overall predicted five years survival of these patients was 71%. This is considerably better than estimated survival curves for most reported series treating variceal hemorrhage using any non-transplant modality. This is even further excentuated with aspect to the markly improved survival of Child class C patients after LT. Of particular importance is the observation that the original liver disease did not influence survival after LT.
Liver transplantation should be only offered to a small and selected number of patients with portal hypertension (84). Its indication has been discussed in patients with liver cirrhosis and Child-Pugh class C or advanced B with progression. However this decision is given independently if the patient has a portal hypertension with esophageal varices or not. Contraindications are continuing alcohol abuse, high morbidity and extrahepatic manifestation of a hepatocellular carcinoma. Furthermore the patients should be very compliant. If the indication for shunt operation in Child-pugh A and B patients because od sclerotherapy failure is discussed the possibility or necessity of a later LT should not be forget. Suitable shunt types for later LT are distal splenorenal shunt and small diameter mesocaval or portocaval shunts with 10 or 12 mm PTFE prothesis side-to-side (82-83). There is no role for an acute transplantation in patients with acute variceal hemorrhage (84). These are candidates for emergency sclerotherapy, TIPS or emergency surgery. Bleeding should be stopped by these modalities to be able to perform later elective LT. However, these data are representative of the subsest of patients with endstage liver failure and must be analysed against the potential limitation of organ procurement. Thus, the role and the application of LT to the therapy of acute variceal hemorrhage is as yet undefined.

Management of the acute bleeding patient

The overall therapeutic goal is to control hemorrhage as rapidly and reliable as possible with minimal complications. The initial resuscitation should include critical monitoring for the sequelae of hepatocellular failure. Thus the patient must be hemodynamically stabilized measures must be institute to provent encephalopathy, coagulation defects should be corrected and electrolyte hemostasis should be monitored.
Emergency endoscopy is mandatory. The suspicion of varices may require inition of combined intravenous vasopressin (0,4 U/min.) and subliqual nitroglycerine (1 Tbl./1/2hourly for 6 hrs.) or Octreotide prior to endoscopy. If the diagnosis is confirmed endoscopically and the expertice is available, immediate sclerotherapy or ligation should be performed. Should the necessary expertise not be available, bleeding should be temporalily controlled by the use of balloon tamponade or drug therapy. Delayed sclerotherapy should be performed within 24 hours. Patients who continue to bleed or who rebleed after sclerotherypy or ligation require rapid identification or preparation for either emergency meso- or portocaval shunt or devascularisation, possibly in combination with staple transsection. Individuals whose bleeding is controlled by sclerotherapy should undergo repeat endoscopic evaluation and injected as needed at weekly or monthly intervals until all visible varices are obliterated or protected by scar tissue. Thereafter appropriate long-term management and follow-up should be instituted. This may include repeated sclerotherapy or ligation or elective planned operation like distal spleno-renal or narrow-lumen mesocaval or portocaval shunt or later LT.

In conclusion, when the ballad of Sir Andrew: "Fight on, my men, Sir Andrew says,
a little I am hurt, but yet not slane,
I will but lie down and bleed awhile,
and then a arise and fight again"

ballad of Sir Andrew Barton (85)is rephrased: we need to reliable predict that who will be hurd and not stand, and prevent them from bleeding awhile but if they should, we need to be sure that they will rise and fight again. Clearly, in odrer to rationalize prophylactic therapeutic intervention, a clearer definition of the patients subsets within the broad classification of esophageal varices is required. Most investigators have been unsuccessful in identifying the one third of patients whose cause will be complicated by hemorrhage (86). Prophylactic intervention will become a realistic goal, when a mean of identifying those at high risk for either hemerrhage or death becomes clear. Hopefully, using similar predictive criteria, preemptive and prioritized LT will become a pragmatic aim. Realistically, the development of rational strategies for surgical therapy in this disease will require a better understanding of the fundamental reason why varices bleed and therapy fails. This, along with improvement in non-operative management and improvement in technology to correct the hepatocellular component, will hopefully help to reduce the discouraging over-all outlook in this disease.


1 - Shoemaker,W.C.: Relationship of oxygen transport patterns to the pathophysiology and therapy of shock states. Intensive Care Med.,13,1987,230-242.
2 - Shumacker,P.T.,Cain,S.M.: The concept of critical oxygen delivery. Intensive Care Med.,13,1987,223-229.
3 - Benoit,J.N.,Womack,W.A.,Hernandez,L. et al.: "Foreward" and "backward" flow mechanisms of portal hypertension. Relative contributions in the rat model of portal vein stenosis. Gastroenterology 185,1989,1092-1096.
4 - Vorobioff,J.,Bredfeldt,J.E.,Groszmann,R.J.: Hyperdynamic circulation in portal hypertensive rat model: a promary factor for maintenance of chronic portal hypertension. Am.J.Physiol., 244,1983,G52-G57.
5 - Sikuler,E.,Kravetz,D.,Groszmann,R.J.: Evolution of portal hypertension in mechanisms involved in its maintenance in a rat model. Am.J.Physiol.,248,1985,G618-G625.
6 - Murray,J.F.,Dawson,A.M.,Sherlock,S.: Circulatory changes in chronic liver disease. Am.J.Med.,24,1958,358-367.
7 - Kantos,H.H.,Shapiro,W.,Mauck,H.P. et al.: General and regional circulatory alterations in cirrhosis of the liver. Am.J.Med.,37,1964,526-535.
8 - Mashford,M.L.,Mahon,W.A.,Chalmers,T.C.: Studies of the cardiovascular system in the hypotension of liver failure. N.Engl.J.Med.,267,1962,1071-1074.
9 - Groszmann,R.J.,Atterbury,C.E.: Portal hypertension: classification and pathogenesis. Semin.Liver.Dis.,2,1982, 177-186.
10 - Vianna,H.,Hayes,P.C.,Moscoso,G. et al.: Normal venous circulation of the gastroesophageal junction.Gastroenterology 93,1987,876-879.
11 - Spence,R.A.J.: The venous anatomy of the lower esophagus in normal subjects and in patients with varices: an image analysis study. Br.J.Surg.,7,1984,739-744.
12 - McCormack,T.T.,Smith,P.M.,Rose,J.D. et al.: Perforating veins and blood flow in esophageal varices. Lancet 11,1983,442-444.
13 - Garcia-Tsao,E.,Groszmann,R.J.,Fisher,R.L. et al.: Portal pressure, presence of esophageal varices and variceal bleeding. Hepatology 5,1985,419-424.
14 - Rector,B.J.,Reynolds,T.B.: Risk factors for hemorrhage from esophageal varices and acute gastric erosions. Clin.Gastroenterol.,14,1985,139-142.
15 - McDougall,B.R.D.,Williams,R.: A controlled trial of cimetidine in the recurrence of variceal hemorrhage. Hepatology 3,1983,69-73.
16 - Rigau,J.,Bosch,J.,Bordaz,J.M. et al.: Endoscopic measurement of variceal pressure in cirrhosis: correlation with portal pressure and variceal hemorrhage. Gastroenterology 69, 1989,873-878.
17 - Adamsons,R.J.,Butt,K.,Dennis,D.R. et al.: Prognostic significance of portal pressure with bleeding esophageal varices. SGO 145,1977,353-357.
18 - De Dombal,F.,Clarke,J.,Clamp,S. et al.: Prognostic factors in upper GI bleeding. Endoscopy 18,1986 (Suppl.2),6-10.
19 - Lebrec,D., De Fleury,P.,Rueff,B. et al.: Portal hypertension, size of esophageal varices and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology 79,1980,1139-1144.
20 - Paquet,K.J.: Prophylactic endoscopic sclerosing treatment of esophageal wall in varices - a prospective controlled randomized trial. Endoscopy 14,1982,4-5.
21 - Westaby,D.,MacDougall,B.R.D.,Saugers,J.B. et al.: A study of risk factors in patients with cirrhosis and variceal bleeding. In.: Westaby,D.,Williams,R.(eds.): Variceal bleeding. London,Pittman,1982.
22 - Polio,J.,Groszmann,R.J.: Haemodynamic factors envolved in the development and rupture of esophageal varices: pathophysiologic approach to treatment. Semin.Liver Dis.,6,1986,318-329.
23 - Piai,G.,Minieri,N.,Catalano,M. et al.: A prospective evaluation of two indices of first variceal bleeding in liver cirrhosis:a prospective follow-up. Gastroenterology 100,1991,A210.
24 - Beppu,K.,Inokuchi,K.,Koyanagi,N. et al.: Prediction of variceal hemorrhage by oesophageal endoscopy. Gastrointest.Endosc.,27,1981,213-218.
25 - North Italian Endoscopy Club for the study and treatment of oesophageal varices: Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and oesophageal varices: a prospective multicentre study. N.Engl.J.Med.,319,1989,983-989.
26 - Burroughs,A.K.: Somatostatin an octreotide for variceal bleeding. J.Hepatol.,13,1981,1-4.
27 - Borroughs,A.K.: Medical management of bleeding esophageal varices. Dig.Dis.,10 (Suppl.1),1992,30-37.
28 - Fleischer,D.: Etiologz an prevalence of severe presistent upper gastrointestinal bleeding. Gastroenterology 94,1981,521-543.
29 - Terblanche,J.,Yakoob,B.H.I.,Bornman,P.c. et al.: Acute bleding varices: a five year prospective evaluation of tamponade and sclerotherapy. Ann.Surg.,194,1981,521-530.
30 - Paquet,K.J.,Käufer,C.,Gütgemann,A.: Die chirurgische Behandlung der Ösophagusvarizenblutung. Dtsch.Med.Wschr., 99, 1974,1259-1262.
31 - Paquet,K.J.,Mercado,M.A.,Aichner,W et al.: Conservative and semiinvasive modalities for treating bleeding esophageal varices. Hepato-Gastroenterol.,37,1990,561-564.
32 - Paquet,K.J.,Feussner,H.: Endoscopic sclerosis and esophageal balloon tamponade in acute hemorrhage from esophagogastric varices: a prospective controlled randomized trial. Hepatology 5,1985,580-583.
33 - Paquet,K.J.,Kalk,J.F.,Koussouris,P.: Immediate endoscopic sclerosis of bleeding esophageal varices: a prospective evaluation over five years. Surg.Endosc.,1,1988,18-23.
34 - Larson,A.W.,Cohen,H.,Zweiban,B. et al.: Acute esophageal variceal sclerotherapy. Results of a prospective randomized controlled trial. JAMA 225,1986,497-500.
35 - Moreto,M.,Zaballa,M.,Bernal,A. et al.: A randomized trial of tamponade or sclerotherapy as immediate treatment for bleeding esophageal varices. SGO 167,1988,303-305.
36 - Bornman.P.C.,Terblanche,J.,Kahn,D. et al.: Limitation of multiple injection sclerotherapy sessions for variceal bleeding. S.Afr.Med.J.,208,1986,34-36.
37 - Paquet,K.J.,Mercado,M.A.,Gad,H.A.: Surgical procedures for bleeding esophagogastric varices when sclerotherapy fails: a prospective study. Am.J.Surg.,160,1990,43-46.
38 - Richter,G.M.,Nöltge,G.,Palmaz,J.C. et al.: The transjugular intrahepatic portosystemic stent-shunt (TIPSS): results of a pilot study. Cardiovasc.Interv.Radiol., 13,1990, 200-207.
39 - Rössle,M.,Nöltge,G.,Haag,K. et al.: TIPSS: clinical experience with an improved technique. Hepatology 14,1991,96A.
40 - MacDougall,B.R.D.,Westaby,D.,Thodossi,A. et al.: Increasec long-term survival in variceal hemorrhage using injection sclerotherapy. Results of a controlled trial. Lancet I,1982,124-127.
41 - Terblanche,J.,Bornman,P.C.,Kahn,D. et al.: Failure of repeated injection sclerotherapy to improve long-term survival after esophageal variceal bleeding. A five years prospective controlled clinical trial. Lancet II,1983,1328-1332.
42 - Soederlund,C.: Endoscopic sclerotherapy of esophageal varices: a clinical study. Acta Chir.Scand.,151,1985,(Suppl.), 1-23.
43 - The Copenhagen Variceal Sclerotherapy Project: sclerotherapy after first variceal hemorrhage in cirrhosis, a randomized multicenter trial. N.Engl.J.Med., 311,1984,1594-1600.
44 - Korula,J.,Balart,L.A.,Radvan,G. et al.: A prospective randomized multicenter trial of chronic esophageal variceal sclerotherapy. Hepatology 5,1985,584-589.
45 - Paquet,K.J.: Indication and early and long-term results of paravariceal immediate, elective and prophylactic injection sclerotherapy. In: Idezuki et al.(eds.): Esophageal varices. Elsevier Scienc.Publ.,B.V.Chapter 27, Amsterdam,1988,1-22.
46 - Paquet,K.J.: Prevention of recurrent bleeding: sclerotherapy. In: Okuda,K.,Benhamou,J.P.(eds.): Portal Hypertension. Springer, Tokyo - Berlin - Heidelberg - New York, 1991,495-507.
47 - Stigman,J.V.,Goff,J.S.,Michalez-Onody,P.A. et al.: Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N.Engl.J.Med.,326,1992,1527-1532.
48 - Newtaba,R.,Jensen,D.M.,Egan,J. et al.: Randomized prospective study of Cyanoacrylate, sclerotherapy or rubber band ligation for endoscopic hemostasis of bleeding canine gastric varices (abstr.).Gastrointes.Endosc.,38,1992,235-236.
49 - Ring,E.J.,Lake,J.R.,Roberts,J.P. et al.: Using transjugular intrahepatic portosystemic shunt to control variceal bleeding before liver transplantation. Ann.Intern.Med., 116,1992,304-309.
50 - Sajal,A.J.,Freedman,A.M.,Shiffman,M.L. et al.: Portosystemic encephalopathy (PSE) following transjugular intrahepatic portosystemic shunt (TIPS): a controlled study (abstract). Hepatology 16,1992,85A.
51 - Sellinger,M., Haag,K.,Ochs,A. et al.: Factors influencing the incidence of hepatic encephalopathy in patients with transjugular intrahepatic portosystemic stent-shunt (TIPS) (abstract). Hepatology 16,1992,122A.
52 - Somberg,K.A.,Reikler,J.L.,Doherty,M. et al.: Hepatic encephalopathy following transjugular intrahepatic portosystemic shunts (TIPS): incidence and risk factors (abstract). Hepatology 16,1992,122A.
53 - Dasarathy,S.,Dwivedi,M.,Bhargava,D. et al.: A prospective randomized trial comparing repeated endoscopic sclerotherapy and propranolol in decompensated (Child class B and C) cirrhotic patients. Hepatology 16,1992,122A.
54 - Dolett,J.M.,Champigneulle,B.,Patrice,A. et al.: Sclerotherapie endoscopique contre propranolol aprés hemorrhagie par rupture de varices oesophagiennes chez le cirrhotique: résultate á 4 an d°une etude randomiseé. Gastroenterol.Clin.Biol.,12,1988,234-239.
55 - Alexandrino,P.T.,Alves,M.M.,Correia,J.P.: Propranolol or endoscopic sclerotherapy in the prevention of recurrence of variceal bleeding: a prospective controlled trial. J.Hepatol., 7,1988,175-185.
56 - Fleig,W.F.,Stange,E.F.,Hunecke,R. et al.: Prevention of recurrent bleeding in cirrhosis with recent variceal hemorrhage: prospective, randomized comparison of propranolol and sclerotherapy. Hepatology 7,1987,355-361.
57 - Westaby,D.,Polson,R.G.,Gimson,A.E.S. et al.: A controlled trial of oral propranolol compared with injection sclerotherapy for long-term management of variceal bleeding. Hepatology 11, 1990,353-359.
58 - Rossi,V.,Cales,P.,Burtin,P. et al.: Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy. J.Hepatol.,12,1991,283-289.
59 - Vinel,J.P.,Lamouliate,H.,Cales,P. et al.: Propranolol reduces the rebleeding rate during endoscopic sclerotherapy before variceal obliteration. Gastroenterology 102,1992,1760-1763.
60 - Ink,O.,Martin,T.,Poynard,T. et al.: Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis? A prospective multicenter, randomize trial. Hepatology 16,1992,912-919.
61 - Warren,W.D., Henderson,J.M.,Millika,W.J. et al.: Distal splenorenal shunt vs. endoscopic sclerotherapy for long-term management of variceal bleeding. Ann.Surg.,203,1986,454-462.
62 - Callo,J.P.,Grendell,J.H.,Crass,R.A. et al.: Endoscopic sclerotherapy vs. portocaval shunt in patients with severe cirhosis and acute variceal hemorrhage. Long-term follow-up. N.Engl.J.Med.,316,1987,11-15.
63 - Teres,J.,Bordas,J.M.,Bravo,D. et al.: Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage. A randomized controlled trial. Hepatology 7,1987, 430-436.
64 - Rikkers,L.F.,Burnett,D.A.,Volentine,G.D. et al.: Shunt surgery vs. endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Ann.Surg.,206,1987,261-267.
65 - Henderson,J.M.,Kutner,M.H.,Millikan,B.J. et al.: Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis. A prospective randomized trial. Ann.Intern.Med.,112,1990, 262-269.
66 - Spina,G.P.,Santambroggio,R.E. et al.: Distal splenorenal shunt vs. endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized controlled trial. Ann.Surg.,211,1990,178-185.
67 - Planas,R.,Boix,J.,Broggi,I. et al.: Portacaval shunt vs. endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 100,1991,1078-1086.
68 - Hassab M.A.: No shunt operations in portal hypertension without cirrhosis. SGO 131,1970,648-654.
69 - Da Silva,L.C.,Straus,E.,Gayotto,L.C. et al.: Arandomized trial for the study of the elective surgical treatment of portal hypertension in mansonic schistosomiasis. Ann.Surg.,204, 1986,148-153.
70 - Osborne,D.R.,Hobbs,K.E.: The acute treatment of hemorrhage from esophageal varices: a comparison of esophageal transsection and staple gun anastomosis with mesocaval shunt. Br.J.Surg.,68,1981,734-737.
71 - Spence,R.A.,Johnston,G.W.: Results in hundred consecutive patients with staple esophageal transsection for varices. SGO 160,1985,323-329.
72 - Suguira,M.,Futagawa,S.: Results of 636 esophageal transsection with paraesophagogastric devascularisation in the treatment of esophageal varices. J.Vasc.Surg.,1,1984,254-260.
73 - Idezuki,Y.,Sanyo,K.,Bandai,Y. et al.: Current strategy for esophhageal varices in Japan. Am.J.Surg.,160,1990,98-104.
74 - Paquet,K.J..,Koussouris,P.,Henkel,M.: Die gaatroösophageal Diskonnektion nach Hassab-Paquet als Therapie de Wahl beim Leberzirrhotiker mit Blutungen aus Magenvarizen, Ösophagusulcera nach Sonden- oder Sklerosierungstherapie und trotz Sklerosierung wiederauftretender Ösophagusvarizenblutungen.
In.: Henning,H., Wurbs,G.(eds.): Fortschritte der gastroenterologischen Endoskopie, Band XVI, Demetr, Gräfelfing, 1987.
75 - Paquet,K.J.,Mercado,M.A.,Koussouris,P. et al.: Sugiura operation in recurrent variceal hemorrhage of patients with portal vein thrombosis after long-term injection sclerotherapy. Dis.Esophag.,3(2),1990,15-22.
76 - Paquet,K.J.: Kollateralisations- und Venensperroperationen.
In: Kremer,K.,Lierse,W.,Platzer,W. et al.: Chirurgische Operationslehre,Bd.V, Peritoneum, Staging Laparotomie, Leber, Pfortader, Milz.Thieme, Sttutgart-New York, 1993, p.167-197.
77 - Vanamaker,S.R.,Cooperman,H.,Carrey,C.: Use of EEA-stapling instrument for control of bleeding esophageal varices. Surgery 94, 1983,620-626.
78 - Hofmann,J.: Stapler transsection of the esophagus for bleeding esophageal varices. Scand.J.Gastroenterol., 18,1983, 707-711.
79 - Huitzinga,W.K.,Angorn,P.A.,Baker,L.W.: Esophageal transsection vs. injection sclerotherapy in the management of bleeding esophageal varices in patients at high risk. SGO 16,1985,539-546.
80 - Gouge,T.H.,Rason,J.H.C.: Esophageal transsection with paraesophageal devascularisation (The Sugiura procedure) for bleeding esophageal varices. Am.J.Surg.,151,1986,47-53.
81 - Johnston,G.W.: Six years experience of esophageal transsection for esophageal varices using a circular stapling gun. GUT 23,1982,770-773.
82 - Esquivel,C.O.,Klintmalm,G.,Iwatsuki,G. et al.: Liver transplantation in patients with patent splenorenal shunt. Surgery 101,1987,430-432.
83 - Mazzaferro,V.,Todo,S.,Tsakis,A.G. et al.: Liver transplantation in patients with previous portosystemic shunts. Am.J.Surg.,160,1990,111-116.
84 - Ringe,B.,Lang,H.,Tusch,G. et al.: The role of liver transplantation in the management of esophageal variceal hemorrhage. World J.Surg.,18,1994,233-239.
85 - Balladof Sir Andrew Barton, autorship unknown. In: Browing,D.C.(eds.): Every men°s dictionary of quotation and proverbs, London, Reader°s Union, 1955, p.431.
86 - Terblanche,J.: Sclerotherapy for prophylaxis of variceal bleeding. Lancet 1985,961-963.

Adresa pro korespondenci:
Hans-Kalk Hospital
Bad Kissingen


Zobrazování jaterních metastáz pomocí značených monoklonálních protilátek

Rubeš T., * Bláha V.
Chirurgická klinika 3.LF UK v Praze
přednosta: Doc.MUDr.J.Fanta,CSc.
* Klinika nukleární mediciny 3.LF UK v Praze
přednosta: Prof.MUDr.V.Bláha,CSc.


Jednou z možností detekce jaterních metastáz je metoda imunoscintigrafická využívající značené monoklonální protilátky. Tato diagnostická metoda je vhodná i k zobrazení primárního nádoru a jeho recidiv.
Autoři uvádějí své zkušenosti s monoklonální antiCEA protilátkou BW 431/26 - Scintium CEA firmy Behring u 54 onkologických nemocných. Z jejich výsledků vyplývá, že imunoscintigrafické vyšetření je výhodnější při vyhledávání metachronních metastáz jater než při zobrazování metastáz synchronních. Nejvýhodnější je užít imunoscintigrafickou metodu k detekci lokální recidivy nádoru.
Klíčová slova : imunoscintigrafie - monoklonální protilátky - jaterní metastázy


Immunoscintigraphy based on monoclonal antibodies is one of the methods used to the detection of liver secundarities. This method is available also for the detection of primary tumor and its recurrence.
Authors describe their experience with monoclonal antiCEA antibody BW 431/26 - Scintium CEA Behring on 54 oncologic patients. On the base of their results authors conclude that immunoscintigraphy is more available for looking up of metachronic liver secundarities than for the detection of synchronic metastatic tumors. The most available is the use of imunoscintigraphy for the diagnosis of local recurrence.
Key words: immunoscintigraphy - monoclonal antibodies - liver metastatic tumors